Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma

Cancer

Volumn 98, Issue 2, 2003, Pages 424-430

  Tanaka, Yoshiko ^a   Kobayashi, Hiroshi ^a   Suzuki, Mika ^a   Kanayama, Naohiro ^a   Suzuki, Mitsuaki ^b   Yamakawa, Toru ^c   Morishita, Hideaki ^c   Terao, Toshihiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Bikunin; Interalpha inhibitor; Ovarian carcinoma; Prognosis

Indexed keywords

MESSENGER RNA; ULINASTATIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSEMINATED CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME;

ADENOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TRYPSIN INHIBITOR, KUNITZ SOYBEAN; TUMOR MARKERS, BIOLOGICAL;

EID: 0037669488     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11506     Document Type: Article

References (35)

1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3-10.
2. Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Invest. 1996;3:99-105.
3. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 1996;49:117-137.
4. Yonemura Y, Nojima N, Kaji M, et al. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer. 1995;76:941-953.
5. Look MP, Foekens JA. Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS. 1999;107:150-159.
6. Conese M, Blasi F. The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol. 1995;8:365-389.
7. Kobayashi H, Shinohara H, Takeuchi K, et al. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res. 1994;54:844-849.
8. Kobayashi H, Shinohara H, Ohi H, et al. Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. Clin Exp Metastasis. 1994;12:117-128.
9. Kobayashi H, Fujie M, Shinohara H, et al. Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. Int J Cancer. 1994;57:378-384.
10. Kobayashi H, Gotoh J, Hirashima Y, et al. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995;270:8361-8366.
11. Kobayashi H, Gotoh J, Kanayama N, et al. Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition. Cancer Res. 1995;55:1847-1852.
12. Kobayashi H, Shinohara H, Gotoh J, et al. Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent. Br J Cancer. 1995;72:1131-1137.
13. Kobayashi H, Shinohara H, Fujie M, et al. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. Int J Cancer. 1995;63:455-462.
14. Kobayashi H, Gotoh J, Terao T. Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells. Eur J Cell Biol. 1996;71:380-386.
15. Kobayashi H, Sugino D, Terao T. Urinary trypsin inhibitor, a Kunitz-type protease inhibitor, modulates tumor necrosis factor-stimulated activation and translocation of protein kinase C in U937 cells. Int J Oncol. 1998;12:95-105.
16. Sugino D, Okushima M, Kobayashi H, et al. Production of a hybrid protein consisting of the N-terminal fragment of urokinase and the C-terminal domain of urinary trypsin inhibitor in Escherichia coli. Biotechnol Appl Biochem. 1998;27:145-152.
17. Kobayashi H, Sugino D, She MY, et al. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur J Biochem. 1998;253:817-826.
18. Kobayashi H, Gotoh J, Fujie M, et al. Characterization of the cellular binding site for the urinary trypsin inhibitor. J Biol Chem. 1994;269:20642-20647.
19. Kobayashi H, Hirashima Y, Sun GW, et al. Identification and characterization of the cell-associated binding protein for urinary trypsin inhibitor. Biochim Biophys Acta. 1998;1383:253-268.
20. Kobayashi H, Hirashima Y, Terao T. Human myometrial cells in culture express specific binding sites for urinary trypsin inhibitor. Mol Hum Reprod. 2000;6:735-742.
21. Hirashima Y, Kobayashi H, Suzuki M, et al. Characterization of binding properties of urinary trypsin inhibitor to cell-associated binding sites on human chondrosarcoma cell line HCS-2/8. J Biol Chem. 2001;276:13650-13656.
22. Suzuki M, Kobayashi H, Tanaka Y, et al. Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins. Biochim Biophys Acta. 2001;1547:26-36.
23. Mizushima S, Nii A, Kato K, et al. Gene expression of the two heavy chains and one light chain forming the inter-alpha-trypsin-inhibitor in human tissues. Biol Pharm Bull. 1998;21:167-169.
24. Lindahl T, Engel G, Ahlgren J, et al. Can axillary dissection be avoided by improved molecular biological diagnosis? Acta Oncol. 2000;39:319-326.
25. Ferrandina G, Ranelletti FO, Lauriola L, et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol. 2002;85:305-310.
26. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:S9-15.
27. Harbeck N, Kates RE, Schmitt M, et al. Clinical relevance of invasion factors, urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol. 2002;20:1000-1007.
28. Okusa Y, Ichikura T, Mochizuki H. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma. Cancer. 1999;85:1033-1038.
29. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002;26:767-771.
30. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994;54:6539-6548.
31. Takanami I, Takeuchi K, Karuke M. Expression of ETS-1 is correlated with urokinase-type plasminogen activator and poor prognosis in pulmonary adenocarcinoma. Tumour Biol. 2001;22:205-210.
32. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1-22.
33. Kobayashi H, Suzuki M, Sun GW, et al. Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor. Biochim Biophys Acta. 2000;1481:310-316.
34. Kobayashi H, Suzuki M, Tanaka Y, et al. Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C-and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem. 2001;276:2015-2022.
35. Bourguignon J, Borghi H, Sesboue R, et al. Immunohistochemical distribution of inter-alpha-trypsin inhibitor chains in normal and malignant human lung tissue. J Histochem Cytochem. 1999;47:1625-1632.